The current results highlight the oncogenic role of METTL1 and the relevance of the METTL1‐m7G‐EGFR/EFEMP1 axis in the BC development, indicating that METTL1 is for improved BC treatment as potential therapeutic target. This evidence concerns the gene METTL1 and breast cancer.